SCHEMBL14721985

SCHEMBL14721985

Cc1cc2cc(N)ccc2n(C)c1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRPF1 P55201 10/20 1.00
PRKCI P41743 1/20 0.46
BRD1 O95696 4/20 0.44
BRD4 O60885 3/20 0.44
BRPF3 Q9ULD4 3/20 0.44
BRD9 Q9H8M2 2/20 0.44
BRD7 Q9NPI1 2/20 0.44
HDAC8 Q9BY41 6/20 0.42
HDAC1 Q13547 3/20 0.42
HDAC6 Q9UBN7 3/20 0.42
TTR P02766 2/20 0.40
TRIM24 O15164 1/20 0.39
DAO P14920 1/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
GLA P06280 1/20 0.39
HPGD P15428 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CYP3A4 P08684 1/20 0.38
ANPEP P15144 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12992386 0.86 BRPF1 (0.75) BRPF1PRKCIBRD1BRD4BRPF3
SCHEMBL20284352 0.81 BRPF1 (0.68) BRPF1PRKCITTRDAOKDM4E
SCHEMBL22421744 0.80 BRPF1 (0.67) BRPF1PRKCIBRD4KDM4EALDH1A1
SCHEMBL22421717 0.79 BRPF1 (0.66) BRPF1PRKCIBRD4KDM4EALDH1A1
SCHEMBL11467250 0.79 BRPF1 (0.65) BRPF1BRD1BRD4BRPF3BRD9
SCHEMBL9250818 0.79 BRPF1 (0.65) BRPF1BRD1BRD4BRPF3BRD9
SCHEMBL31202639 0.79 BRPF1 (0.65) BRPF1BRD1BRD4BRPF3BRD9
SCHEMBL22421773 0.78 BRPF1 (0.64) BRPF1PRKCIBRD4KDM4EALDH1A1
SCHEMBL3481207 0.77 BRPF1 (0.62) BRPF1PRKCIKDM4EALDH1A1HPGD
SCHEMBL31036167 0.77 BRPF1 (0.62) BRPF1PRKCIKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025076470-A1 SOX10 INHIBITORS AND USES THEREOF THE GENERAL HOSPITAL CORPORATION (US) 2025-04-10 WO disclosed
EP-3555063-B1 6-AMINO-QUINOLINONE COMPOUNDS AND DERIVATIVES AS BCL6 INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2020-09-16 EP disclosed
US-20170291875-A1 QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS UCL BUSINESS PLC (GB) 2017-10-12 US disclosed
US-20170291875-A1 QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS UCL BUSINESS PLC (GB) 2017-10-12 US disclosed
US-20170291875-A1 QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS UCL BUSINESS PLC (GB) 2017-10-12 US disclosed
WO-2016034512-A1 QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS UCL BUSINESS PLC (GB) 2016-03-10 WO disclosed
WO-2013027168-A1 NOVEL HETEROCYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS PFIZER INC. (US) 2013-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170291875-A1 QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS BRD4, BRPF3, BRD3 BRPF1 104/4885PRKCI 2074/4885BRD1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.